Inventiva (NASDAQ:IVA) Shares Down 4.9% - What's Next?

Key Points

• Inventiva shares fell 4.9% to about $3.60 in Monday trading, with volume down 90% from the stock’s average daily level.
• Analyst sentiment remains broadly positive: the stock has an average “Buy” rating and a consensus price target of $15.75, despite one “Sell” rating.
• Institutional investors have increased exposure, with hedge funds and other institutions owning 19.06% of Inventiva. The company’s lead candidate, lanifibranor, is in late-stage development for MASH, a liver disease involving inflammation and fibrosis.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) fell 4.9% during trading on Monday . The company traded as low as $3.62 and last traded at $3.5950. Approximately 70,300 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 717,108 shares. The stock had previously closed at $3.78.

Analyst Upgrades and Downgrades

IVA has been the topic of several research analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inventiva in a research note on Friday, July 17th. Piper Sandler reaffirmed an "overweight" rating on shares of Inventiva in a report on Wednesday. Guggenheim upped their price objective on shares of Inventiva from $11.00 to $14.00 and gave the company a "buy" rating in a research note on Tuesday, September 15th. Finally, Cantor Fitzgerald assumed coverage on Inventiva in a research note on Friday, July 17th. They set an "overweight" rating for the company. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $15.75.

Inventiva Stock Performance

The firm has a 50 day simple moving average of $4.52 and a two-hundred day simple moving average of $4.85.

Institutional Investors Weigh In On Inventiva

Large investors have recently made changes to their positions in the business. Engineers Gate Manager LP raised its holdings in shares of Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock worth $269,000 after purchasing an additional 43,280 shares during the period. Seven Fleet Capital Management LP bought a new stake in Inventiva during the 1st quarter valued at $1,111,000. Persistent Asset Partners Ltd purchased a new stake in Inventiva during the 4th quarter worth about $603,000. NEXTBio Capital Management LP bought a new position in shares of Inventiva in the fourth quarter valued at approximately $6,039,000. Finally, Eventide Asset Management LLC purchased a new position in shares of Inventiva during the 4th quarter valued at $1,155,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva's lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.